The stock of telemedicine provider Hims & Hers has been under intense pressure, shedding approximately 38% of its value since October. This decline persists despite the company posting robust revenue growth, creating a stark disconnect that management is now attempting to address with a decisive move: a new $250 million share repurchase program. This aggressive buyback initiative raises a critical question for investors: is this a confident signal of intrinsic value, or a defensive maneuver in a deepening downturn?
Strong Growth Meets Softer Outlook
Operationally, Hims & Hers continues to demonstrate impressive expansion. Third-quarter revenue surged by 49% to reach $600 million. However, the market’s focus has shifted sharply toward future challenges. A disappointing forecast for the fourth quarter and concerns over margin pressures have overshadowed these strong results. Furthermore, increased competition in the lucrative market for GLP-1 weight-loss medications—a sector dominated by players like Novo Nordisk—has added to investor anxiety.
It is against this backdrop that the board authorized the substantial buyback. The timing, following the weaker guidance, is interpreted by many as a clear statement that leadership believes the market is significantly undervaluing the company’s long-term prospects.
Market Sentiment Remains Cautious
While the executive team maintains skin in the game, broader market indicators reflect caution. Notably, CEO Andrew Dudum recently restructured large shareholdings between various trusts for estate planning purposes, without executing sales. Similarly, COO Michael Chi gifted 5,000 shares. These actions suggest continued insider commitment.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Yet, the options market tells a different story. The put-call ratio currently stands at 0.53, and implied volatility has spiked above 68%, signaling that traders are bracing for continued significant price swings. This environment has even spurred financial product innovation, with GraniteShares launching a specialized ETF (HMYY) designed to capitalize on Hims & Hers’ volatility by selling put options on leveraged ETFs.
Analyst Perspective and Strategic Pivots
Wall Street analysts are taking a measured view. Bank of America, for instance, has set a price target of $32 per share, which sits about 20% below the stock’s recent trading level. In response to its challenges, Hims & Hers is not relying on financial engineering alone. The company is actively diversifying its revenue streams through new initiatives like “Labs,” a service offering at-home testing kits.
The central dilemma for investors remains unresolved. The share buyback is a powerful tool, but whether it represents a strategic display of strength or the last line of defense against a persistent downtrend will depend on the company’s ability to navigate its competitive hurdles and return to delivering on both growth and profitability expectations.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from December 3 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 3.
Hims & Hers: Buy or sell? Read more here...
